ZIOPHARM Oncology Information Available through S&P Market Access Program
NEW YORK, NY - January 06, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today that its company information will be made available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information readily available and disseminated to users of Standard & Poor's Advisor Insight. In addition, the Company announced that its shares are Depository Trust Company (DTC) eligible. The DTC is a registered clearing agency with the Securities and Exchange Commission.
Company information available through S&P's Advisor Insight program includes share price, volume, dividends, shares outstanding, company financial position, and earnings. Standard & Poor's Advisor Insight is an internet-based research engine used by more than 100,000 investment advisors. A public version of the site is available at www.advisorinsight.com Information about companies in Standard & Poor's Market Access Program will be available via S&P's Stock Guide database, which is distributed electronically to virtually all major quote vendors. As part of the program, a full description of ZIOPHARM Oncology will also be published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in approximately 37 states under the Blue Sky Laws.
About ZIOPHARM Oncology, Inc.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights in molecular and cancer biology to efficacious, but highly toxic therapies and re-engineers them to provide more effective and safer cancer therapy for patients. For more information, visit www.ziopharm.com.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, and the Company's reliance on third parties to develop its product candidates. The Company assumes no obligation to update these forward-looking statements, except as required by law.
Manager, Investor Relations/Communication